Biocryst Pharmaceuticals buy Wedbush
Start price
25.02.25
/
50%
€7.80
Target price
25.02.26
€14.28
Performance (%)
-19.22%
End price
26.02.26
€6.30
Summary
This prediction ended on 26.02.26 with a price of €6.30. The prediction for Biocryst Pharmaceuticals disappointed with a performance of -19.22%. Wedbush has a follow-up prediction for Biocryst Pharmaceuticals where he still thinks Biocryst Pharmaceuticals is a Buy. Wedbush has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Biocryst Pharmaceuticals | 19.437% | 19.437% | 17.172% |
| iShares Core DAX® | -4.932% | -11.977% | -3.485% |
| iShares Nasdaq 100 | -2.634% | -2.218% | 13.783% |
| iShares Nikkei 225® | -4.733% | -10.900% | 19.712% |
| iShares S&P 500 | -2.544% | -3.540% | 8.878% |
Comments by Wedbush for this prediction
In the thread Biocryst Pharmaceuticals diskutieren
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is now covered by analysts at Wedbush. They set an "outperform" rating and a $15.00 price target on the stock.
Ratings data for BCRX provided by MarketBeat
In the thread Trading Biocryst Pharmaceuticals
Die von Wedbush gewählte maximale Laufzeit wurde überschritten
Current prediction by Wedbush for Biocryst Pharmaceuticals
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€7.60
30.06.25
30.06.25
€15.36
30.06.26
30.06.26
12.65%
21:53
21:53
